GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Sale Of Business

Akari Therapeutics (FRA:CLA) Sale Of Business : €0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics Sale Of Business?

Akari Therapeutics's sale of business for the three months ended in Mar. 2024 was €0.00 Mil. It means Akari Therapeutics gained €0.00 Mil from selling business. Akari Therapeutics's sale of business for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Compared with last quarter (€0.00 Mil in Dec. 2023 ), Akari Therapeutics gained the same money from selling business in Mar. 2024 (€0.00 Mil).


Akari Therapeutics Sale Of Business Historical Data

The historical data trend for Akari Therapeutics's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Sale Of Business Chart

Akari Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Business
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Akari Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24
Sale Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Akari Therapeutics Sale Of Business Calculation

The amount earned to sell business.


Sale Of Business for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akari Therapeutics Sale Of Business Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.


Akari Therapeutics (FRA:CLA) Business Description

Traded in Other Exchanges
Address
75/76 Wimpole Street, London, GBR, W1G 9RT
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. It operates mainly in United States and United Kingdom.

Akari Therapeutics (FRA:CLA) Headlines

From GuruFocus

Ouster to Host Virtual Investor Day on February 22, 2021

By Business Wire Business Wire 02-16-2021

Carl Bass to Join Ouster as Chairman of the Board of Directors

By Business Wire Business Wire 02-17-2021

Ouster to Present at Upcoming Investor Conferences

By Business Wire Business Wire 03-01-2021